Samsung and Medtronic returned to back a $35m round for diabetes patient monitoring technology developer Glooko that included Insulet and Mayo Clinic.
Glooko, the US-based producer of a remote diabetes patient monitoring system, secured $35m in funding on Tuesday from a consortium featuring consumer electronics company Samsung and medical device manufacturer Medtronic.
Diabetes equipment supplier Insulet and medical research group Mayo Clinic also took part in the round, which was led by growth equity firm Georgian Partners and backed by Canaan Partners and Social Capital. Samsung took part through early-stage investment unit Samsung Next.
Glooko operates a cloud-based diabetes management platform that…
